TABLE 1.
Group mortality and survival data and time to death
| Group | Product | Dose or dilution (day[s] administered)a | No. of survivors/total no. | % survival | Time to death (days) |
||
|---|---|---|---|---|---|---|---|
| Avg | SD | Range | |||||
| 1 | Buffer | NAb | 0/16 | 0 | 4.6 | 1.4 | 3.1–8.7 |
| 2 | AdVAV | 7.5 × 107 vp (0) | 29/32 | 91 | 5.2 | 0.6 | 4.8–5.8 |
| 3 | AdVAV | 1.5 × 109 vp (0) | 31/32 | 97 | 4.1 | NA | NA |
| 4 | AdVAV | 3.5 × 1010 vp (0) | 32/32 | 100 | NA | NA | NA |
| 5 | AdVAV | 3.5 × 1010 vp (0, 28) | 31/32 | 97 | 6.1 | NA | NA |
| 6 | AVA | 1:16 (0, 28) | 31/32 | 97 | 3.0 | NA | NA |
| 7 | AVA | 1:64 (0, 28) | 25/32 | 78 | 4.5 | 0.8 | 3.8–6.1 |
a
The vaccine dose is shown as viral particles (vp) for AdVAV or as a dilution for the AVA vaccine.
b
NA, not applicable.